Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor path... - 0 views
-
Nathan Goodyear on 27 Nov 12low-dose naltrexone (NLD) is shown to inhibit growth in vivo. This is important as it has implications in cancer therapies. This study found a greater benefit with LDN and exogenous opioid growth factor (OGF).